Literature DB >> 7905528

Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity?

M E Nevins1, E W Anthony.   

Abstract

The current study evaluated three serotonin-3 (5-HT3) antagonists for potential anxiolytic effects in rats by using the fear-potentiated startle paradigm. Because initial studies did not show an effect of the 5-HT3 antagonists, the authors explored the question of whether altering the training conditions under which the conditioned fear is formed would alter the sensitivity of the paradigm to the effects of the 5-HT3 antagonists. Two fear-conditioning protocols were used: 1) 10 conditioning trials on each of 2 days using 0.5 mA of foot shock and 2) 15 conditioning trials in 1 day using 0.25 mA of foot shock. Ondansetron (0.001-1.0 mg/kg), (R)-zacopride (0.0001-1.0 mg/kg), granisetron (0.001-1.0 mg/kg), diazepam (0.32-3.2 mg/kg) and buspirone (0.56-5.6 mg/kg) were evaluated for their ability to reduce the potentiated startle produced by both conditioning protocols. Although diazepam and buspirone effectively reduced the potentiated startle produced by both protocols, the 5-HT3 antagonists were potently effective only in the second protocol. Subsequent experiments demonstrated that the 5-HT3 antagonists block startle potentiation only when the lower (i.e., 0.25 mA) shock intensity is used during training. These results suggest the possibility that different conditioning protocols may produce qualitatively different anxiety states, which can be differentiated by the 5-HT3 antagonists, but not by diazepam or buspirone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905528

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  A novel subpopulation of 5-HT type 3A receptor subunit immunoreactive interneurons in the rat basolateral amygdala.

Authors:  F Mascagni; A J McDonald
Journal:  Neuroscience       Date:  2006-12-05       Impact factor: 3.590

Review 2.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

4.  Improvements in hippocampal-dependent learning and decremental attention in 5-HT(3) receptor overexpressing mice.

Authors:  Amber V Harrell; Andrea M Allan
Journal:  Learn Mem       Date:  2003 Sep-Oct       Impact factor: 2.460

5.  Fear-potentiated startle response is remarkably similar in two laboratories.

Authors:  R J Joordens; T H Hijzen; B W Peeters; B Olivier
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

6.  The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon.

Authors:  M Morales; F E Bloom
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

7.  Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.

Authors:  G R Dawson; N M Rupniak; S D Iversen; R Curnow; S Tye; K J Stanhope; M D Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

Review 8.  Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.

Authors:  Y E Yarker; D McTavish
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

9.  5HT(3) antagonism abolishes the emotion potentiated startle effect in humans.

Authors:  Catherine J Harmer; Catriona B Reid; Manaan Kar Ray; Guy M Goodwin; Philip J Cowen
Journal:  Psychopharmacology (Berl)       Date:  2006-03-30       Impact factor: 4.530

10.  Serotonergic innervation and serotonin receptor expression of NPY-producing neurons in the rat lateral and basolateral amygdaloid nuclei.

Authors:  M Bonn; A Schmitt; K-P Lesch; E J Van Bockstaele; E Asan
Journal:  Brain Struct Funct       Date:  2012-04-17       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.